What is the price target for KYTX stock?
12 analysts have analysed KYTX and the average price target is 30.19 USD. This implies a price increase of 240.38% is expected in the next year compared to the current price of 8.87.
NASDAQ:KYTX • US5019761049
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KYVERNA THERAPEUTICS INC (KYTX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-12-16 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-04 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-30 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-08 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-20 | William Blair | Initiate | Outperform |
| 2025-05-27 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-04-03 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2025-04-01 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-11-20 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2024-11-15 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-10-10 | UBS | Initiate | Buy |
| 2024-09-19 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-08-15 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2024-07-31 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-07-16 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-07-03 | HC Wainwright & Co. | Initiate | Neutral |
| 2024-03-04 | JP Morgan | Initiate | Overweight |
| 2024-03-04 | Morgan Stanley | Initiate | Overweight |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 5.656M | 7.025M 24.20% | -100.00% | 16.475M | 54.238M 229.21% | 178.04M 228.26% | 534.23M 200.06% | 868.94M 62.65% | 1.41B 62.27% | 1.79B 26.95% | ||||
| EBITDA YoY % growth | -25.76M | -28.333M -9.99% | -63.196M -114.23% | -145.973M -132.07% | -173.469M -23.14% | -183.814M -5.96% | -194.584M -5.86% | -221.625M -13.90% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -26.346M | -29.384M -11.53% | -63.082M -112.38% | -144.88M -129.14% | -178.913M -25.11% | -199.15M -11.31% | -216.452M -8.69% | -419.22M -93.68% | -425.34M -1.46% | -134.64M 68.35% | N/A | N/A | N/A | |
| Operating Margin | -465.81% | -418.28% | N/A | N/A | N/A | N/A | -1,313.82% | -772.93% | -238.90% | -25.20% | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -8.79 | -3.36 60.53% | -3.78 -5.19% | -3.11 14.67% | -3.04 2.51% | -2.49 18.03% | -3.67 -47.54% | -1.09 70.28% | 2.06 288.79% | 6.22 201.98% | 8.51 36.72% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.77 25.56% | -0.79 19.03% | -0.77 9.00% | -0.80 -0.09% | -0.88 -14.41% | -0.90 -14.29% | -0.93 -20.00% | -0.96 -19.75% | -0.32 63.95% | -0.11 87.50% | 0.30 131.87% | 0.66 169.15% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||||
| EBITDA Q2Q % growth | -41.82M 10.84% | -42.84M 1.28% | -43.86M -17.60% | -44.88M -19.73% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -43.554M 8.13% | -44.944M -1.20% | -46.232M -19.38% | -48.743M -24.09% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
12 analysts have analysed KYTX and the average price target is 30.19 USD. This implies a price increase of 240.38% is expected in the next year compared to the current price of 8.87.
KYVERNA THERAPEUTICS INC (KYTX) will report earnings on 2026-05-19.
The consensus EPS estimate for the next earnings of KYVERNA THERAPEUTICS INC (KYTX) is -0.77 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering KYVERNA THERAPEUTICS INC (KYTX) is 12.